Rallybio Corporation (RLYB)
NASDAQ: RLYB
· Real-Time Price · USD
0.36
-0.04 (-8.86%)
At close: Jun 09, 2025, 3:59 PM
-8.86% (1D)
| Bid | 0.32 |
| Market Cap | 15.1M |
| Revenue (ttm) | 848K |
| Net Income (ttm) | -48.19M |
| EPS (ttm) | -1.07 |
| PE Ratio (ttm) | -0.34 |
| Forward PE | -0.28 |
| Analyst | Hold |
| Ask | 0.42 |
| Volume | 139,931 |
| Avg. Volume (20D) | 162,177 |
| Open | 0.39 |
| Previous Close | 0.40 |
| Day's Range | 0.36 - 0.40 |
| 52-Week Range | 0.22 - 1.73 |
| Beta | -1.24 |
About RLYB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RLYB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RLYB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAITNEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastati...